Humana (NYSE:HUM – Get Rating) had its target price raised by Mizuho from $500.00 to $529.00 in a research report released on Thursday morning, The Fly reports. They currently have a maintains rating on the insurance provider’s stock.
HUM has been the topic of a number of other reports. UBS Group raised shares of Humana from a neutral rating to a buy rating and boosted their price objective for the company from $486.00 to $520.00 in a report on Wednesday, April 13th. Wells Fargo & Company upped their price target on shares of Humana from $512.00 to $514.00 and gave the company an overweight rating in a report on Wednesday, May 25th. Sanford C. Bernstein initiated coverage on shares of Humana in a report on Thursday, May 26th. They issued a market perform rating and a $506.00 price target on the stock. StockNews.com raised shares of Humana from a buy rating to a strong-buy rating in a report on Wednesday, April 20th. Finally, Loop Capital initiated coverage on shares of Humana in a report on Thursday, June 16th. They issued a buy rating and a $510.00 price target on the stock. Five research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of Moderate Buy and a consensus price target of $511.44.
Humana Price Performance
Shares of HUM opened at $482.00 on Thursday. The firm has a market capitalization of $60.97 billion, a PE ratio of 20.45, a price-to-earnings-growth ratio of 1.42 and a beta of 0.80. The company has a debt-to-equity ratio of 0.74, a current ratio of 1.53 and a quick ratio of 1.53. Humana has a 1-year low of $351.20 and a 1-year high of $497.47. The company’s fifty day moving average price is $462.13 and its 200-day moving average price is $440.76.
Insider Buying and Selling
In related news, insider Samir Deshpande sold 3,957 shares of the company’s stock in a transaction dated Tuesday, May 3rd. The shares were sold at an average price of $434.19, for a total transaction of $1,718,089.83. Following the completion of the transaction, the insider now owns 5,529 shares in the company, valued at approximately $2,400,636.51. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Insiders own 0.39% of the company’s stock.
Institutional Inflows and Outflows
Several hedge funds have recently modified their holdings of HUM. Tcwp LLC acquired a new position in shares of Humana during the 1st quarter worth about $25,000. WFA of San Diego LLC acquired a new stake in Humana in the 2nd quarter valued at about $30,000. BerganKDV Wealth Management LLC raised its holdings in Humana by 885.7% in the 4th quarter. BerganKDV Wealth Management LLC now owns 69 shares of the insurance provider’s stock valued at $32,000 after acquiring an additional 62 shares during the last quarter. Riverview Trust Co acquired a new stake in Humana in the 1st quarter valued at about $32,000. Finally, Newbridge Financial Services Group Inc. raised its holdings in Humana by 42.3% in the 2nd quarter. Newbridge Financial Services Group Inc. now owns 74 shares of the insurance provider’s stock valued at $35,000 after acquiring an additional 22 shares during the last quarter. Institutional investors and hedge funds own 94.93% of the company’s stock.
Humana Company Profile
Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. It operates through three segments: Retail, Group and Specialty, and Healthcare Services. The company offers medical and supplemental benefit plans to individuals. It also has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.
- Get a free copy of the StockNews.com research report on Humana (HUM)
- Use These To Find Your Stock’s Support and Resistance Levels
- Is Boeing Stock is Ready for Lift-Off ?
- Elon Musk is Out, But Should You Be In Twitter Stock?
- 3 Earnings Announcements That Could Surprise
- Twitter’s Up For Third Week In A Row: What’s Next For The Stock?
Want More Great Investing Ideas?
- Bear Market Game Plan!
- The 10 Best Stocks to Own in 2022
- 7 Stocks to Buy and Hold Forever
- 3 Stocks to DOUBLE This Year
Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.